Weakly-basic composite bone cement material, and preparation method therefor and use thereof
By using weakly alkaline borosilicate bioactive glass, adjusting its composition to reduce the pH value of the degradation product, the problem of PMMA bone cement in the body is solved, and the biological activity and biological of composite bone cement materials are improved. Safety promotes osteogenic differentiation and osteointegration of stem cells.
Patent Information
- Application Number
- PCT/CN2023/096054
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-24
- Publication Date
- 2024-11-28
AI Technical Summary
The existing PMMA bone cement forms a highly alkaline microenvironment after degradation in the body, inhibits tissue regeneration and leads to biosafety risks, and limits the high content doping of bioactive glass in composite materials.
Weakly alkaline borosilicate bioactive glass, by adjusting its composition, reducing the pH value of the degradation product, we prepare high-biologically and low-basic composite bone cement materials, and increase the content of borosilicate bioactive glass to Improve biological performance.
It significantly reduces the hemolytic reaction of composite bone cement materials, improves cell survival and in vitro cytocompatibility, provides a suitable weakly alkaline microenvironment to promote osteogenesis and differentiation of stem cells, and enhances osteointegration and osteogenesis regeneration ability.
Smart Images

Figure CN2023096054_28112024_PF_FP_ABST
Abstract
Description
A weakly alkaline composite bone cement material and its preparation method and application Technical Field
[0001] The invention belongs to the technical field of medical materials and relates to a weakly alkaline composite bone cement material and a preparation method and application thereof. Background Art
[0002] With the intensification of an aging society, the demand for tissue repair and regeneration caused by aging has become one of the major problems facing society. For example, osteoporotic fractures have directly led to a significant increase in the demand for bone repair biomaterials.
[0003] Polymethyl methacrylate (PMMA) bone cement is widely used in orthopedic repair materials due to its high mechanical strength, good plasticity, and rapid curing at room temperature. It is also gradually being used to cover diabetic skin ulcers and rapidly revascularize them. However, due to the biological inertness of PMMA, it can only form a fibrous wrapping after implantation in the body and cannot form a strong bony interface with the bone. Therefore, after a period of time, implantation into the osteoporotic vertebral defect is prone to problems such as slippage and displacement, which can cause back pain and adjacent vertebral fractures in patients, thus limiting the application of PMMA bone cement in the field of bone repair materials.
[0004] To address these shortcomings, some research teams have incorporated bioactive glass into a PMMA bone cement matrix to impart certain bioactivity and osseointegration properties to PMMA bone cement. For example, CN104922731A (Invention Title: Preparation Method and Application of Composite Bone Cement Precursor, Strontium Borate Bioglass / Polymethyl Methacrylate Composite Bone Cement) discloses that bioactive glass, when incorporated into an inert material matrix, can effectively impart bioactivity and osseointegration properties. However, the composite bone cement disclosed in this patent forms a highly alkaline microenvironment upon degradation, posing a safety hazard to the human body. For example, after bioactive glass-based materials are implanted into local bone tissue, the excessively alkaline microenvironment can inhibit the activity and functional expression of cells involved in tissue regeneration, and may even lead to hemolysis. Another example is the use of bioactive glass in skin repair. The highly alkaline microenvironment formed after degradation can cause a burning sensation in the skin, potentially increasing local inflammation. Therefore, due to the highly alkaline microenvironment formed after implantation and degradation in the body, the content of bioactive glass incorporated into the matrix of tissue repair composite materials is often insufficient, which in turn limits the improvement of the composite material's biological properties.
[0005] Therefore, it is necessary to optimize the excessively alkaline microenvironment formed after the degradation of bioactive glass to achieve high-content bioactive glass doping in the composite matrix, thereby preparing a composite material with both high bioactivity and low alkalinity to achieve better in vivo biosafety and tissue regeneration and repair performance.
[0006] Summary of the Invention
[0007] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention proposes a weakly alkaline composite bone cement material and its preparation method and application. The composite bone cement material of the present invention includes weakly alkaline borosilicate bioactive glass and polymethyl methacrylate (PMMA). The weakly alkaline borosilicate bioactive glass becomes weakly alkaline after degradation. Therefore, in the composite bone cement material, the amount of weakly alkaline borosilicate bioactive glass added is high, so that the composite bone cement material has high bioactivity characteristics, and optimizes the in vitro and in vivo biosafety and tissue repair performance of the composite bone cement.
[0008] A first aspect of the present invention provides a weakly alkaline composite bone cement material.
[0009] Specifically, a weakly alkaline composite bone cement material includes a solid component and a liquid component;
[0010] The solid components include weakly alkaline borosilicate bioactive glass, polymethyl methacrylate (PMMA), and a developer;
[0011] The liquid component includes methyl methacrylate (MMA) and a polymerization activator;
[0012] The chemical composition of the weakly alkaline borosilicate bioactive glass is aXO·bB2O3·cP2O5·dSiO2·eY2O, wherein a, b, c, d and e are molar fractions, a is 4-39, b is 5-15, 17-35, 37-53 or 55-65, c is 1-10, d is 0-60, e is 2-12, X is one or more of Ca, Mg, and Sr, and Y is Na and / or K.
[0013] Preferably, the developer comprises zirconium oxide and / or barium sulfate.
[0014] Preferably, the solid component further comprises benzoyl peroxide (BPO).
[0015] Preferably, the polymerization activator comprises N,N-dimethyl-p-toluidine and / or hydroquinone.
[0016] Preferably, in the weakly alkaline borosilicate bioactive glass, the value of e ranges from 5 to 10. When Y is both Na and K, e represents the sum of the molar fractions of Na2O and K2O.
[0017] Preferably, in the weakly alkaline borosilicate bioactive glass, the value of a ranges from 34 to 39. When X is Ca, Mg, and Sr at the same time, a represents the sum of the molar fractions of MgO, CaO, and SrO.
[0018] Preferably, the chemical composition of the weakly alkaline borosilicate bioactive glass is 3Na2O·2K2O·8MgO·25CaO·27B2O3·2P2O5·27SiO2·6SrO, 3Na2O·4K2O·8MgO·23CaO·27B2O3·2P2O5·27SiO2·6SrO, 4Na2O·6K2O·8MgO·20CaO·27B2O3·2P2O5·27SiO2·6SrO or 3Na2O·4K2O·8MgO·16CaO·27B2O3·2P2O5·27SiO2·13SrO.
[0019] Preferably, the weakly alkaline borosilicate bioactive glass further comprises ZnO and / or CuO.
[0020] Preferably, the number average molecular weight of the polymethyl methacrylate is 300,000-1.5 million; further preferably, the number average molecular weight of the polymethyl methacrylate is 400,000-1,000,000.
[0021] Preferably, the mass percentage of the weakly alkaline borosilicate bioactive glass in the solid component is greater than 20% and less than or equal to 70%; further preferably, the mass percentage of the weakly alkaline borosilicate bioactive glass in the solid component is greater than 20% and less than or equal to 60%; more preferably, the mass percentage of the weakly alkaline borosilicate bioactive glass in the solid component is 30-50%.
[0022] Preferably, the mass percentage of the developer in the solid component is 18-32%; further preferably, the mass percentage of the developer in the solid component is 20-30%.
[0023] Preferably, the mass percentage of the benzoyl peroxide in the solid component is 0.1-1.6%; further preferably, the mass percentage of the benzoyl peroxide in the solid component is 0.2-1.5%.
[0024] Preferably, the solid components, calculated by mass percentage, include 20.1-60% weakly alkaline borosilicate bioactive glass, 30-61.9% polymethyl methacrylate (PMMA), and 10-39.9% developer.
[0025] Preferably, the solid components, calculated by mass percentage, include 20.1-60% weak alkaline borosilicate bioactive glass, 8.5-59.7% polymethyl methacrylate (PMMA), 20-30% developer, and 0.2-1.5% benzoyl peroxide.
[0026] Preferably, in the liquid component, the mass percentage of methyl methacrylate (MMA) is 90-99.5%, preferably 95-99.5%.
[0027] Preferably, the mass percentage of the polymerization activator in the liquid component is 0.5-10%, preferably 0.5-5%.
[0028] Preferably, the content of hydroquinone in the liquid component does not exceed 50 ppm, preferably 30-50 ppm.
[0029] Preferably, the liquid component comprises, by weight percentage, 95-99.5% of methyl methacrylate and 0.5-5% of N,N-dimethyl-p-toluidine.
[0030] Preferably, in the weakly alkaline composite bone cement material, the mass volume ratio of the solid component to the liquid component is (2.1-3.0) g:1 mL; further preferably, in the weakly alkaline composite bone cement material, the mass volume ratio of the solid component to the liquid component is (2.1-2.7) g:1 mL; more preferably, in the weakly alkaline composite bone cement material, the mass volume ratio of the solid component to the liquid component is (2.3-2.5) g:1 mL.
[0031] Preferably, the solid component is in powder form.
[0032] Preferably, in the solid component, the particle size of the weakly alkaline borosilicate bioactive glass is 30-55 μm, preferably 40-50 μm.
[0033] Preferably, in the solid component, the particle size of the polymethyl methacrylate is 10-90 μm, preferably 20-80 μm.
[0034] A second aspect of the present invention provides a method for preparing a weakly alkaline composite bone cement material.
[0035] Specifically, a method for preparing a weakly alkaline composite bone cement material comprises the following steps:
[0036] Preparation of the solid component: weighing raw material components for preparing the weakly alkaline borosilicate bioactive glass, mixing, melting, cooling, and crushing to obtain the weakly alkaline borosilicate bioactive glass, and then mixing the weakly alkaline borosilicate bioactive glass, polymethyl methacrylate, and a developer to obtain the solid component;
[0037] Preparation of the liquid component: mixing the methyl methacrylate (MMA) and a polymerization activator to prepare the liquid component;
[0038] The solid and liquid components are mixed.
[0039] Preferably, the raw material components for preparing the weakly alkaline borosilicate bioactive glass include sodium salt, potassium salt, magnesium salt, calcium salt, strontium salt, silicon dioxide, boric acid, and phosphate.
[0040] More preferably, the sodium salt, potassium salt, magnesium salt, calcium salt, strontium salt refers to the carbonate or bicarbonate corresponding to sodium, potassium, magnesium, calcium, and strontium.
[0041] Preferably, the preparation process of the solid component further includes crushing and ball milling operations after cooling.
[0042] When the composite bone cement material is used, the solid component and the liquid component are mixed according to a certain proportion.
[0043] The third aspect of the present invention provides an application of a weakly alkaline composite bone cement material.
[0044] A tissue repair material comprises the composite bone cement material.
[0045] Preferably, the tissue repair material includes a skin repair material or a bone repair material.
[0046] Although previous borosilicate bioactive glass has good bioactivity, it cannot be incorporated into the PMMA bone cement matrix in large quantities. One important reason is that the degradation of borosilicate bioactive glass will cause strong alkalinity, which can easily cause biosafety issues such as hemolysis and cytotoxicity. The incorporation of low content of borosilicate bioactive glass does not significantly improve the biological effect of PMMA bone cement. Therefore, the present invention adjusts the components of borosilicate bioactive glass to prepare weakly alkaline borosilicate bioactive glass, which significantly reduces the high alkaline pH effect caused by its immersion and degradation in specific solutions.
[0047] Compared with the prior art, the present invention has the following beneficial effects:
[0048] (1) The composite bone cement material of the present invention includes weakly alkaline borosilicate bioactive glass. The present invention adjusts the composition of the weakly alkaline borosilicate bioactive glass to reduce the pH value of its degradation products, thereby achieving the effect of weak alkalinity after degradation. The weak alkalinity can greatly improve the survival rate of cells and significantly reduce the hemolytic reaction caused by high alkalinity, thereby significantly improving its in vitro cell compatibility.
[0049] (2) Although osteogenesis requires a certain alkaline environment, only under relatively appropriate weak alkaline conditions can the directional osteogenic differentiation of stem cells be effectively mediated, osteoblast activity be enhanced, and osteoclast activity be inhibited. When the alkalinity is too high, it will inhibit the proliferation and differentiation of stem cells, inhibit the activity of osteoclasts, and damage the host tissue. Therefore, based on the theory of alkalinity regulating osteogenesis, the alkaline environment is not the higher the better, but requires a specific weak alkaline microenvironment. The weak alkaline composite bone cement material provided by the present invention can provide the weak alkaline microenvironment required to achieve the best osteogenesis-promoting effect.
[0050] (3) The weakly alkaline borosilicate bioactive glass content in the composite bone cement material of the present invention exceeds 20% of the solid components, for example, 30-60%, which is significantly higher than the borosilicate bioactive glass content in the bone cement material of CN104922731A. Therefore, the present invention can significantly improve the in vivo and in vitro biological properties of the PMMA-based composite bone cement, including bioactivity, osteointegration, and bone regeneration capacity.
[0051] (4) The preparation method of the composite bone cement material provided by the present invention has readily available raw materials, simple process, convenient operation, and is easy to use. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 shows the mechanical properties of the composite bone cement materials of Examples 1-3;
[0053] FIG2 shows the hemolysis rates of the composite bone cement materials of Examples 1-3 and Comparative Examples 1-3;
[0054] FIG3 shows the hemolysis rates corresponding to the composite bone cement materials of Examples 4-6;
[0055] FIG4 shows the survival of hBMSCs cells in culture medium containing 10% (mass concentration) CCK-8 reagent at different pH values on days 1, 3, and 7;
[0056] FIG5 is a live cell staining image of hBMSCs cells under different pH conditions for 1, 3, 5 and 7 days;
[0057] FIG6 shows the ALP staining and ALPL gene mRNA expression levels of hBMSCs cells after osteogenic induction for 3, 5, 7, and 10 days under different pH conditions;
[0058] Figure 7 shows (a) COL1A1 immunocytochemistry; (b) relative fluorescence intensity; (c) COL1A1 gene mRNA expression level; (d) Sirius red staining of hMSCs after 10 days of osteogenic induction under different pH conditions;
[0059] Figure 8 shows (a) Alizarin red staining of hBMSCs after osteogenic induction at different pH values for 7, 10, and 14 days; (b) Alizarin red semi-quantification;
[0060] FIG9 shows the mRNA expression levels of the osteogenic-related gene SP7 in hBMSCs cells after osteogenic induction for 3, 7, 10 and 14 days under different pH conditions. DETAILED DESCRIPTION
[0061] In order to make the technical solution of the present invention more clearly understood by those skilled in the art, the following examples are given for illustration. It should be noted that the following examples do not limit the scope of protection claimed by the present invention.
[0062] Unless otherwise specified, the raw materials, reagents, or devices used in the following examples can be obtained from conventional commercial sources or by existing known methods.
[0063] Example 1
[0064] A composite bone cement material comprising a solid component and a liquid component;
[0065] The solid components, calculated by weight percentage, include 30% weak alkaline borosilicate bioactive glass, 60% polymethyl methacrylate (PMMA) powder, and 10% developer (ZrO2).
[0066] The liquid component, calculated by weight percentage, comprises 99.2% of methyl methacrylate (MMA) and 0.8% of N,N-dimethyl-p-toluidine (DMPT);
[0067] The chemical composition of weakly alkaline borosilicate bioactive glass is 3Na2O·2K2O·8MgO·25CaO·27B2O3·2P2O5·27SiO2·6SrO.
[0068] A method for preparing a weakly alkaline composite bone cement material comprises the following steps:
[0069] (1) Preparation of solid components:
[0070] Preparation of weakly alkaline borosilicate bioactive glass:
[0071] Weigh 5.23g Na2CO3, 13.64gK2CO3, 38.34g(MgCO3)4·Mg(OH)2·5H2O, 123.48g CaCO3, 169.7g H3BO3, 80.05g SiO 2:, 43.71 g SrCO₃, and 30.79 g NaH₂PO₄·2H₂O were added to a container, stirred and mixed, and then poured into a platinum crucible and placed in a high-temperature furnace. The crucible was heated at 1200°C for 1 hour, and then directly poured into ice water. The glass was removed, washed with alcohol, and dried in a drying oven. After drying, it was ball-milled in a ball mill for 1 hour. Finally, a vibrating screen was used to screen out weakly alkaline borosilicate bioactive glass with a particle size of 40-45 μm.
[0072] The weakly alkaline borosilicate bioactive glass accounts for 30% by weight of the solid component. The weakly alkaline borosilicate bioactive glass, PMMA powder and ZrO2 are placed in a three-dimensional mixer and uniformly mixed (50 Hz, 2 hours) to obtain a solid component.
[0073] (2) Preparation of liquid components:
[0074] Methyl methacrylate (MMA) and N,N-dimethyl-p-toluidine (DMPT) are mixed to obtain a liquid component;
[0075] (3) Preparation of composite bone cement materials:
[0076] At room temperature, the solid component and the liquid component are mixed at a mass volume ratio of 2.4 g:1 mL and stirred evenly to prepare a composite bone cement material.
[0077] Example 2
[0078] A method for preparing a weakly alkaline composite bone cement material, wherein weakly alkaline borosilicate bioactive glass accounts for 40% of the solid component by mass, polymethyl methacrylate (PMMA) powder accounts for 40%, and a developer (ZrO2) accounts for 20%. The remaining process is the same as in Example 1.
[0079] Example 3
[0080] A method for preparing a weakly alkaline composite bone cement material, wherein weakly alkaline borosilicate bioactive glass accounts for 50% of the solid component by mass, polymethyl methacrylate (PMMA) powder accounts for 40%, and a developer (ZrO2) accounts for 10%. The remaining process is the same as in Example 1.
[0081] Example 4
[0082] A weakly alkaline borosilicate bioactive glass, designated as weakly alkaline borosilicate bioactive glass-1, was prepared. Its chemical composition was 3Na2O·4K2O·8MgO·23CaO·27B2O3·2P2O5·27SiO2·6SrO. The preparation process was as follows: 5.23g Na2CO3, 27.08g K2CO3, 38.34g (MgCO3)4·Mg(OH)2·5H2O, 112.75g CaCO3, 169.7g H3BO3, 80.05g SiO 2: , 43.71 g SrCO3, and 30.79 g NaH2PO4·2H2O were added to a container, and the remaining steps were exactly the same as the method for preparing weakly alkaline borosilicate bioactive glass described in Example 1.
[0083] The weakly alkaline borosilicate bioactive glass prepared in this example was substituted for the weakly alkaline borosilicate bioactive glass in Example 1 to prepare the composite bone cement material, and the remaining steps were completely consistent with Example 1.
[0084] Example 5
[0085] A weakly alkaline borosilicate bioactive glass, designated as weakly alkaline borosilicate bioactive glass-2, was prepared. Its chemical composition was 4Na2O·6K2O·8MgO·20CaO·27B2O3·2P2O5·27SiO2·6SrO. The preparation process was as follows: 10.3g Na2CO3, 40.29g K2CO3, 38.34g (MgCO3)4·Mg(OH)2·5H2O, 97.26g CaCO3, 169.7g H3BO3, 80.05g SiO 2: , 43.71 g SrCO3, and 30.79 g NaH2PO4·2H2O were added to a container, and the remaining steps were exactly the same as the method for preparing weakly alkaline borosilicate bioactive glass described in Example 1.
[0086] The weakly alkaline borosilicate bioactive glass prepared in this example was substituted for the weakly alkaline borosilicate bioactive glass in Example 1 to prepare the composite bone cement material, and the remaining steps were completely consistent with Example 1.
[0087] Example 6
[0088] A weakly alkaline borosilicate bioactive glass, designated as weakly alkaline borosilicate bioactive glass-3, was prepared. Its chemical composition is 3Na2O·4K2O·8MgO·16CaO·27B2O3·2P2O5·27SiO2·13SrO. The preparation process is as follows: 5.23g Na2CO3, 27.08g K2CO3, 38.34g (MgCO3)4·Mg(OH)2·5H2O, 75.96g CaCO3, 169.7g H3BO3, 80.05g SiO 2: , 91.03 g SrCO 3 , and 30.79 g NaH 2 PO 4 ·2H 2 O were added to a container, and the remaining steps were exactly the same as the method for preparing weakly alkaline borosilicate bioactive glass described in Example 1.
[0089] The weakly alkaline borosilicate bioactive glass prepared in this example was substituted for the weakly alkaline borosilicate bioactive glass in Example 1 to prepare the composite bone cement material, and the remaining steps were completely consistent with Example 1.
[0090] Comparative Example 1
[0091] Compared with Example 1, the only difference in Comparative Example 1 is that the composition of the borosilicate bioactive glass used is: 6Na2O·8K2O·8MgO·16CaO·27B2O3·2P2O5·27SiO2·6SrO (called conventional borosilicate bioactive glass), and the rest of the process is the same as in Example 1.
[0092] Comparative Example 2
[0093] Compared with Example 2, the only difference in Comparative Example 2 is that the composition of the borosilicate bioactive glass used is: 6Na2O·8K2O·8MgO·16CaO·27B2O3·2P2O5·27SiO2·6SrO (called conventional borosilicate bioactive glass), and the rest of the process is the same as in Example 2.
[0094] Comparative Example 3
[0095] Compared with Example 3, the only difference in Comparative Example 3 is that the composition of the borosilicate bioactive glass used is: 6Na2O·8K2O·8MgO·16CaO·27B2O3·2P2O5·27SiO2·6SrO (called conventional borosilicate bioactive glass), and the rest of the process is the same as in Example 3.
[0096] Product effect testing
[0097] 1. Mechanical properties test
[0098] The composite bone cement material of Examples 1-3 was injected into a mold and cured at room temperature for 1 hour to obtain a composite bone cement specimen having a length of (75±0.1) mm, a width of (10±0.1) mm, and a thickness of (3.3±0.1) mm. Four-point bending strength and flexural modulus tests were performed.
[0099] The composite bone cement material of Examples 1-3 was injected into a mold and taken out after curing at room temperature for 1 hour to obtain a cylindrical specimen. The composite bone cement material specimen after polishing had a length of (12±0.1) mm and a diameter of (6±0.1) mm, and a compressive strength test was performed.
[0100] Figure 1 shows the mechanical properties of the composite bone cement materials of Examples 1-3; (a) in Figure 1 (the horizontal axis "weakly alkaline borosilicate bioactive glass content" in Figure 1 indicates that the mass percentage of weakly alkaline borosilicate bioactive glass in the solid component of the composite bone cement material is 30%, 40%, and 50%, respectively, corresponding to Example 1, Example 2, and Example 3, respectively; the dotted line in Figure 1 is the standard value specified in YY 0459-2003) is the four-point bending strength test result, (b) in Figure 1 is the flexural modulus test result, and (c) in Figure 1 is the compressive strength test result.
[0101] As can be seen from Figure 1, the four-point bending strengths measured for the composite bone cement material specimens of Examples 1-3 are 54.81±1.73 MPa (Example 1), 54.14±1.93 MPa (Example 2), and 53.29±2.01 MPa (Example 3), respectively; the flexural modulus is 3766.02±83.93 MPa (Example 1), 3861.51±74.19 MPa (Example 2), and 3866.86±62.79 MPa (Example 3), respectively; the compressive strength is 86.28±3.18 MPa (Example 1), 90.64±2.96 MPa (Example 2), and 88.71±3.63 MPa (Example 3).
[0102] The above results show that the composite bone cement materials prepared in Examples 1-3 of the present invention have good mechanical properties.
[0103] The same mechanical property test was also performed on the composite bone cement materials of Examples 4-6. The test results showed that the mechanical results all met the standard requirements specified in YY 0459-2003, and there was no significant difference in the mechanical properties between Examples 4-6.
[0104] 2. Soaking pH test
[0105] The composite bone cement material samples prepared in Examples 1-3 were immersed in physiological saline and incubated in a 37° C. incubator for 2 hours. The pH value of the immersion solution was measured. The same experiment was performed on Comparative Examples 1, 2, and 3.
[0106] The pH values of the immersion solutions of the composite bone cement materials of Examples 1-3 were 8.89 (Example 1), 8.93 (Example 2), and 9.12 (Example 3), respectively, while the pH values of the conventional borosilicate bioactive glass composite bone cement materials were 10.46 (Comparative Example 1), 10.73 (Comparative Example 2), and 10.81 (Comparative Example 3), indicating that the alkaline pH of the composite bone cement material samples of Examples 1-3 after degradation was significantly reduced, thereby optimizing their biosafety in the body.
[0107] The same test was performed on the composite bone cement materials of Examples 4-6. The test results showed that they also had a relatively low pH value compared with the pH value of conventional borosilicate bioactive glass composite bone cement materials, which was similar to the results of the test in Examples 1-3.
[0108] 3. Hemolysis Test
[0109] Hemolysis experiments were conducted on the composite bone cement material samples prepared in Examples 1 to 3. The same experiments were conducted on Comparative Examples 1 to 3.
[0110] FIG2 shows the hemolysis rates of the composite bone cement materials of Examples 1-3 and the composite bone cement materials of Comparative Examples 1-3.
[0111] As can be seen from Figure 2 (the dotted line in Figure 2 is the standard value specified in YY / T 1651.1-2019, and 30%, 40%, and 50% refer to the content of weakly alkaline borosilicate bioactive glass or conventional borosilicate bioactive glass in the solid component, respectively), the hemolysis rates of the composite bone cement materials of Examples 1-3 are 1.39±0.21% (Example 1), 2.34±0.35% (Example 2), and 4.69±0.29% (Example 3), respectively. The corresponding hemolysis rates of Comparative Examples 1-3 are 23.47±1.24% (Comparative Example 1), 42.06±2.25% (Comparative Example 2), and 49.18±1.99% (Comparative Example 3), respectively. This indicates that the composite bone cement materials prepared in Examples 1-3 have a much lower hemolysis rate than the composite bone cement materials of Comparative Examples 1-3, and have better biosafety.
[0112] The same hemolysis test was performed on the composite bone cement samples prepared in Examples 4-6. The experimental results (Figure 3) show that the hemolysis rates of the composite bone cement materials in Examples 4-6 were 1.58±0.37% (Example 4), 4.60±0.47% (Example 5), and 2.67±0.33% (Example 6), respectively. This indicates that the composite bone cement materials prepared in Examples 4-6 have hemolysis rates comparable to those of the composite bone cement materials in Examples 1-3, and all have excellent biosafety.
[0113] 4. Effect of pH on the proliferation of human bone marrow mesenchymal stem cells (hBMSCs)
[0114] hBMSCs were seeded at 5000 cells / well in a 96-well plate and cultured in α-MEM medium with different pH values for 1, 3, and 7 days, respectively. The medium was then aspirated and replaced with a medium containing 10% (mass concentration) CCK-8 reagent (serum-free). The cells were incubated in a cell culture incubator for 1 hour, and the absorbance was measured at 450 nm using a microplate reader. The results are shown in Figure 4.
[0115] Figure 4 shows the survival status of hBMSCs cells on days 1, 3, and 7 in culture medium containing 10% (mass concentration) CCK-8 reagent at different pH values ("Control" in Figure 4 indicates the control group, "Absorbance@450nm" indicates the absorbance corresponding to 450nm, and "Time(day)" indicates "time(day)"; "*" indicates p < 0.05, "**" indicates p < 0.01, "***" indicates p < 0.001, and "****" indicates p < 0.0001 compared with the Control group).
[0116] As shown in Figure 4, on day 1, there were no significant differences in cell viability across all groups. On day 3, compared to the control group (pH 7.350), the absorbance of the pH 7.650 and 7.800 groups showed no significant difference, while the absorbance of the pH 7.050, 6.750, and 7.950 groups was lower. On day 7, the absorbance of the control group and the pH 7.650 and 7.800 groups increased significantly compared to day 3, indicating that cell proliferation was normal and unaffected. This indicates that hBMSC cell proliferation was not significantly affected in a weakly alkaline environment within the pH range of 7.650-7.800. However, the absorbance of the pH 7.050 and 7.950 groups increased less than that of the pH 7.350, 7.650, and 7.800 groups on day 3, and the absorbance on day 7 was significantly lower than that of the control group. This indicates that pH values greater than 7.800 and less than 7.350 significantly affect cell metabolism, inhibiting cell proliferation and reducing cell survival. The absorbance in the pH 6.750 group was even lower than on day 3, suggesting that under these conditions, cells may begin to undergo apoptosis. In summary, hBMSCs can maintain normal physiological metabolic activity within a pH range of 7.350-7.800, demonstrating that a weakly alkaline environment is crucial for cellular physiology.
[0117] 5. Effect of alkaline microenvironment on hBMSCs cell survival
[0118] hBMSCs were seeded at 4 × 10,000 cells / well in a 24-well plate and cultured in α-MEM medium with different pH values for 1, 3, 5, and 7 days, respectively. The medium was then aspirated and Calcein-AM / PI reagent (a live-dead cell double staining reagent) was added. The cells were incubated in a cell culture incubator for 30 minutes, and the live-dead status of the cells was observed using a fluorescence microscope. The results are shown in Figure 5.
[0119] Figure 5 shows live cell staining images of hBMSCs cells under different pH conditions for 1, 3, 5 and 7 days ("Control" represents the control group, "Day1", "Day3", "Day5" and "Day7" represent day 1, day 3, day 5 and day 7 respectively).
[0120] As shown in Figure 5, over time, the cell number in the five groups with a pH range of 7.050-7.950 gradually increased, and the cell arrangement became denser. In contrast, the cell survival rate and cell number in the pH 6.750 group decreased significantly, with fewer viable cells remaining at 7 days. Cell morphology was also significantly affected, with increased intercellular spaces, sparser arrangement, and shrunken individual cells. At 1 day, the pH 7.050, 6.750, and 7.950 groups showed the greatest impact, with shrunken cell morphology. The pH 7.650 and 7.800 groups showed no significant difference from the control group. These results indicate that under conditions slightly more acidic than physiological conditions (pH < 7.050), hBMSC cell proliferation is significantly inhibited, while a slightly alkaline environment (pH 7.650-7.800) has minimal effects on hBMSC cell proliferation and morphology, with virtually no significant changes compared to physiological conditions. This suggests that a weakly alkaline environment is beneficial for cell growth.
[0121] 6. Effect of alkaline microenvironment on alkaline phosphatase (ALP) expression in hBMSCs
[0122] After hBMSCs were induced to differentiate into osteoblasts for 3, 5, 7, and 10 days, the expression of alkaline phosphatase (ALP) in the cells was detected using the Beyotime BCIP / NBT alkaline phosphatase colorimetric kit. The results are shown in FIG6 .
[0123] Figure 6 shows the ALP staining and ALPL gene mRNA expression levels of hBMSCs cells after osteogenic induction for 3, 5, 7 and 10 days under different pH conditions ("Control" indicates the control group, "Day3", "Day5", "Day7" and "Day10" indicate the 3rd day, 5th day, 7th day and 10th day respectively; "Fold change" indicates the fold difference, and "Time (day)" indicates time (day)).
[0124] Figure 6(a) shows the results of ALP staining of hBMSCs. The blue-purple portion represents ALP, and darker colors indicate higher enzyme levels. As shown in Figure 6(a), the ALP staining color deepened in all groups with increasing days of osteogenic induction, indicating increased ALP expression. At 5 days, the color of the pH 7.650 group was darker than that of the control group, and similarly, it was significantly darker than the control group at 7 days. The color of the pH 7.850 group was not significantly different from the control group. qPCR was used to detect ALPL mRNA expression levels (as shown in Figure 6(b)). The results of ALP staining indicate that ALPL mRNA expression levels increased in all groups with increasing days of osteogenic induction, consistent with the ALP staining results. At 5 days, ALPL mRNA expression levels were significantly higher in the pH 7.650 group compared to the control group. Combined with the ALP staining results, this suggests that the slightly alkaline extracellular environment of pH 7.650 promotes ALP expression in hBMSCs.
[0125] 7. Effect of alkaline microenvironment on COL1A1 expression in hBMSCs
[0126] After hBMSCs were induced to differentiate into osteoblasts for 10 days, the mRNA expression of the COL1A1 gene was tested using Picro Sirius Red staining from Abcam. COL1A1 was also detected using cell immunofluorescence. The results are shown in FIG7 .
[0127] Figure 7 shows (a) COL1A1 immunocytochemistry; (b) relative fluorescence intensity; (c) COL1A1 mRNA expression level; and (d) Sirius Red staining of hMSCs after 10 days of osteogenic induction under different pH conditions ("control" in Figure 7 indicates the control group, "DAPI" indicates 4',6-diamidino-2-phenylindole, "Merged" indicates merged, "Relative fluorescence intensity for COL1A1staining" indicates the relative fluorescence intensity of COL1A1 staining, "Fold change" indicates the fold change, and "Picro-Sirius Red (10 days)" indicates Sirius Red staining at 10 days; "**" indicates p < 0.01, and "***" indicates p < 0.001).
[0128] Figures 7 (a) and (b) show immunofluorescence images and semi-quantitative analysis of relative fluorescence intensity of hBMSCs after 10 days of osteogenic induction. The green portion represents type I collagen alpha 1 chain (COL1A1) protein. As can be seen, under slightly acidic conditions (pH 7.050), COL1A1 protein expression was significantly lower than in the control group, demonstrating a significant difference. However, expression was higher within the pH range of 7.650-7.800, with a significant difference observed in the pH 7.650 group compared to the control group.
[0129] From the expression level of COL1A1 gene mRNA (Figure 7 (c)), it can be seen that in the pH range of 7.650-7.800, the mRNA expression of COL1A1 gene was significantly upregulated compared with the control group, while the expression of the pH groups of 6.750, 7.050 and 7.950 was not significantly different from that of the control group.
[0130] hBMSCs were further stained for collagen using Sirius Red stain. The red portion represents collagen. As shown in Figure 7(d), under slightly acidic conditions (6.750-7.050) compared to physiological conditions, collagen expression decreased, and cell morphology and proliferation were significantly altered, with cell proliferation inhibited and the cells shrinking. Under alkaline conditions (7.650-7.800) compared to physiological conditions, collagen expression increased. However, type I collagen expression did not increase with increasing alkalinity. In the pH 7.950 group, collagen expression was significantly reduced, and cell morphology also changed significantly. These results indicate that collagen expression in hBMSCs is promoted only under slightly alkaline conditions (7.650-7.800). pH values outside a certain range affect both cell survival and morphology, leading to changes in protein expression under these conditions. This is consistent with the results of COL1A1 mRNA expression. Combined with the results of COL1A1 cell immunofluorescence, mRNA expression level and Sirius red staining, it was shown that an alkaline environment within a certain range (pH 7.650-7.800) can promote the expression of type I collagen in hMSCs cells, while an environment beyond this range may affect cell metabolism, thereby reducing protein expression.
[0131] 8. Effect of alkaline microenvironment on the formation of mineralized calcium nodules in hBMSCs
[0132] After hMSCs were induced to differentiate into osteoblasts for 3, 7, 10, and 14 days, the mineralized calcium nodules of the cells were detected using Solebold's Alizarin Red staining solution. The results are shown in FIG8 .
[0133] Figure 8 shows (a) Alizarin red staining of hBMSCs cells after 7, 10 and 14 days of osteogenic induction under different pH conditions; (b) Alizarin red semi-quantitative analysis ("Day" in Figure 8 indicates day, "Alizarin red S" indicates Alizarin red staining, and "control" indicates control group; "Alizarin red S Absorbance@562nm" indicates the absorbance corresponding to 562nm of Alizarin red staining, and "Time(day)" indicates time (day); "*" indicates p < 0.05, "**" indicates p < 0.01, "***" indicates p < 0.001, and "****" indicates p < 0.0001 compared with the control group).
[0134] As can be seen from Figure 8, at 7 days, mineralized calcium nodules were produced in the pH 7.650 and 7.800 groups, and the expression level was significantly higher than that of the control group at 10 days. Under physiological conditions (pH 7.35-7.45), mineralized calcium nodules are usually formed at 14 days of osteogenic induction differentiation. In a slightly alkaline environment (pH 7.650-7.800) that is slightly more physiological, the number of mineralized calcium nodules at 14 days increased significantly compared with the control group, while no mineralized calcium nodules were formed in the pH 7.950 group. The reason may be that in an overly alkaline environment, cell proliferation is affected and it is not suitable for the synthesis of cell osteogenic-related proteins such as extracellular matrix, so mineralized calcium nodules cannot be formed. In addition, it was found that no mineralized calcium nodules were formed under conditions of pH <7.350. The results showed that with the increase of alkalinity, the formation of mineralization increased, but only under conditions slightly alkaline to the physiological environment (pH 7.650-7.800) could the formation of hBMSCs mineralized calcium nodules be promoted. Excessively alkaline conditions (pH greater than 7.950) may affect cell metabolism.
[0135] 9. Effect of alkaline microenvironment on the expression of osteogenic-related genes in hBMSCs
[0136] The expression of the osteogenesis-related gene SP7 was detected at 3, 7, 10, and 14 days after osteogenesis induction. The results are shown in FIG9 .
[0137] Figure 9 shows the mRNA expression levels of the osteoblast-related gene SP7 in hBMSCs cells after osteoblast induction for 3, 7, 10, and 14 days under different pH conditions ("Flod change" indicates the fold change, "Time (day)" indicates time (day); "*" indicates p < 0.05, and "**" indicates p < 0.01).
[0138] As shown in Figure 9, the expression of the SP7 gene increased with the increase of the number of days, and it was found that the expression level of the SP7 gene in the pH 7.650 group was significantly higher than that in the control group.
[0139] Obviously, the above embodiments are merely examples for clarity of explanation and are not intended to limit the implementation methods. Those skilled in the art will readily appreciate that other variations or modifications based on the above descriptions are possible. It is not necessary and impossible to enumerate all implementation methods here. Obvious variations or modifications arising therefrom remain within the scope of protection of the present invention.
Claims
1. A composite bone cement material, It is characterized in that including a solid component and a liquid component; The solid components include weakly alkaline borosilicate bioactive glass, polymethyl methacrylate, and a developer; The liquid component includes methyl methacrylate and a polymerization activator; The chemical composition of the weakly alkaline borosilicate bioactive glass is aXO·bB 2 O 3 ·cP 2 O 5 dSiO 2 ·eY 2 O, wherein a, b, c, d and e are molar fractions, a is 4-39, b is 5-15, 17-35, 37-53 or 55-65, c is 1-10, d is 0-60, e is 2-12, X is one or more of Ca, Mg, Sr, and Y is Na and / or K.
2. The composite bone cement material according to claim 1, It is characterized in that The developer includes zirconium oxide and / or barium sulfate.
3. The composite bone cement material according to claim 1, It is characterized in that The solid component also includes benzoyl peroxide.
4. The composite bone cement material according to claim 1, It is characterized in that In the weakly alkaline borosilicate bioactive glass, the value of e ranges from 5 to 10.
5. The composite bone cement material according to claim 1, It is characterized in that In the weakly alkaline borosilicate bioactive glass, the value range of a is 34-39.
6. The composite bone cement material according to claim 1, It is characterized in that The chemical composition of the weakly alkaline borosilicate bioactive glass is 3Na 2 O.2K 2 O·8MgO·25CaO·27B 2 O 3 2P 2 O 5 ·27SiO 2 6SrO, 3Na 2 O.4K 2 O·8MgO·23CaO·27B 2 O 3 ·2P 2 O 5 ·27SiO 2 6SrO, 4Na 2 O.6K 2 O·8MgO·20CaO·27B 2 O 3 ·2P 2 O 5 ·27SiO 2 6SrO or 3Na 2 O.4K 2 O·8MgO·16CaO·27B 2 O3·2P 2 O 5 ·27SiO 2 ·13SrO.
7. The composite bone cement material according to claim 1, It is characterized in that The weakly alkaline borosilicate bioactive glass also includes ZnO and / or CuO.
8. The composite bone cement material according to any one of claims 1 to 7, It is characterized in that The mass percentage of the weakly alkaline borosilicate bioactive glass in the solid component is greater than 20% and less than or equal to 60%.
9. The composite bone cement material according to any one of claims 1 to 7, It is characterized in that The solid components, in terms of mass percentage, include 20.1-60% weak alkaline borosilicate bioactive glass, 30-61.9% polymethyl methacrylate, and 10-39.9% developer.
10. The composite bone cement material according to claim 8, It is characterized in that In the weakly alkaline composite bone cement material, the mass volume ratio of the solid component to the liquid component is (2.1-3.0) g:1 mL.
11. A method for preparing the composite bone cement material according to any one of claims 1 to 10, It is characterized in that The following steps are involved: Preparation of solid components: weighing raw material components for preparing the weakly alkaline borosilicate bioactive glass, mixing, melting, cooling, and crushing to obtain the weakly alkaline borosilicate bioactive glass, and then mixing the weakly alkaline borosilicate bioactive glass, polymethyl methacrylate, and a developer to obtain the solid component; Preparation of the liquid component: mixing the methyl methacrylate and a polymerization activator to obtain the liquid component; The solid components and liquid components are mixed.
12. A tissue repair material, It is characterized in that The composite bone cement material comprises the composite bone cement material according to any one of claims 1 to 10.
Citation Information
Patent Citations
Compound bone cement precursor as well as preparation method and application of strontium borate bioglass / polymethyl methacrylate compound bone cement
CN104922731A
Ordered porous composite material as well as preparation method and application thereof
CN112546305A
Bio-glass composite bone cement and electric field treatment method
CN112791233A
A bioactive nanocomposite calcium phosphate bone cement composition and a kit for preparing the same
KR1020160060492A
Borosilicate bioactive glass micro-nano particle, preparation method therefor and application thereof
WO2022120768A1
